The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | The role of CRC predicative biomarkers in guiding treatment decisions
Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, comments on the utility of current predicative biomarkers in developing treatment strategies for patients with colorectal cancer (CRC). High microsatellite instability (MSI-H) is currently the best indicator for robust responses to immunotherapy compared to PD-L1 and tumor mutational burden (TMB). However, patients with microsatellite stable (MSS) CRC with a very high TMB may additionally benefit from immunotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
